|
by Bill Roberts - Oxandrolone (Anavar, Oxandrin),
unlike most oral compounds is categorized as a Class
I anabolic steroid, most efficiently stacked with
Class II compounds such as Dianabol or Anadrol.
It adds little if anything to high-dose use of
Class I anabolic steroids such as trenbolone, or
to high-dose testosterone, which is classified as
having mixed activity. It can be an aid, albeit
an expensive one, to moderate dose testosterone
usage.
Oxandrolone has often been called a weak steroid.
Part of the reason for this is that use of a Class
I steroid alone never is maximally effective. The
other cause is that bodybuilders and authors in
the field sometimes make unfortunate and unreasonable
comparisons when judging anabolic steroids. If say
8 tablets per day does little, then a drug is pronounced
useless or weak. And traditionally, oxandrolone
was available in 2.5 mg Anavar tablets, proving
only 20 mg daily with such usage, which totals to
only 140 mg/week. For comparison, testosterone at
that dose also gives little results. Indeed, few
anabolic steroids give dramatic results at that
dose, but they are not called weak on that account.
The proper conclusion is that such Anavar tablets
were individually weak, but not that the drug lacks
potency.
As higher-dose oxandrolone tablets have become
available, the oxandrolone's reputation has improved.
However, it still is not a particularly cost-effective
Class I steroid, and if used alone cannot match
the performance of a good stack.
Pharmacologically, it has been found that oxandrolone
binds weakly to the androgen receptor. This seems
inconsistent with the Class I / Class II system,
but it is what has been found. Perhaps it is the
case that what occurs in the body is not the same
as occurs in in vitro study, or perhaps there is
another interesting phenomenon occurring.
From the practical standpoint, however, oxandrolone's
stacking behavior requires that it be classified
as a Class I steroid: it combines synergistically
with those categorized as Class II, but only additively
with Class I compounds. From the practical standpoint,
it is a rather potent drug – that is to say, it
has good effectiveness per milligram. Stacked with
a Class II steroid, oxandrolone is quite effective
at only 75 mg/day, or even 50.
Oxandrolone does not aromatize or convert to
DHT, and has an 8 hour half-life. Thus, a moderate
dose taken in the morning is largely out of the
system by night, yet supplies reasonable levels
of androgen during the day and early evening.
One study found oxandrolone to be superior to
testosterone and to nandrolone for reducing abdominal
fat in men, or at least in obese older men at the
specific low doses studied, which were not necessarily
equipotent. From this, some have made broad generalizations
to bodybuilding. However, this does not necessarily
carry over to anabolic steroid cycles at doses commonly
used in bodybuilding. In the case of the study in
question, I expect the difference in outcomes was
dose-related.
In practice, at total androgen doses typically
used, one can cut just as effectively without oxandrolone
as with, given any of various possible substitutions
for the oxandrolone. This is not to say this drug
is ineffective, but rather that other androgens
including testosterone are also effective at high
dose for abdominal fat loss.
In the case of low-dose use however, I do think
it is a correct conclusion that for most, low dose
oxandrolone use is more effective for cutting than
equal dosages of most other anabolic steroids. This
may be partly or entirely from additive effect with
natural testosterone: such oxandrolone use may not
suppress such its production, the user may enjoy
both the full effect of his natural testosterone
and the effect of the oxandrolone. In contrast,
low-dose testosterone or nandrolone use results
in substantial suppression of natural testosterone,
and so there is less total effect.
Oxandrolone, as with other 17-alkylated steroids,
is hepatotoxic. At one time it was thought that
it is not, but both clinical and practical experience
with Oxandrin has shown that liver toxicity can
indeed be an issue with prolonged use. I believe
the usual principle of limiting 17-alkylated use
to 6 weeks at a time should be applied when oxandrolone
is used, just as with any alkylated oral.
Trenbolone or Primobolan are suitable substitutes
for oxandrolone, without the liver toxicity issues.
As a substitute, Primobolan shares the property
of being low-suppressive, while trenbolone does
not.
An interesting application of the drug that takes
advantage of its oral administration is use as a
morning-only bridging agent between cycles, which
in my opinion should be done – if done – only after
fully recovering normal testosterone production
from the last cycle. At least 20 mg is usually acceptable
in this application. Ideally, testosterone levels
will be measured to monitor such bridging. A factor
limiting to such bridging is the liver toxicity
issue.
With regard to use by women, while there is a
common belief that oxandrolone is minimally virilizing
to female, in fact virilization is not unusual at
20 mg/day and can occur at considerably lower doses
than that. Even 5 mg/day is not side-effect-free
for all.
During a cycle, oxandrolone is not particularly
recommended because there are more cost-efficient
choices that will fully accomplish the same goals
and do not add to liver toxicity.
The two best uses for oxandrolone are in optional
bridging periods between cycles, if such are employed,
while keeping care to avoid excessive duration of
continuous 17-alkylated use; and, if short-acting
injectables are not available, to supplement cycles
as levels fall between the time of last injection
and the start of post-cycle therapy so that that
time period can remain effective for gains.
Oxandrolone is the chemical name of
active ingredient in Oxandrin and Anavar. Anavar was originally the registered
trademark of Searle Laboratories.
Oxandrin is a registered trademark of Bio-Technology
General Corp. in the United States and/or other
countries.
Anavar Resources
Anavar Pictures
Oxandrin Prescribing Information
 |

|
| Substance name |
Oxandrolone [USAN:INN] |
| Chemical name |
17ß-hydroxy-17a-methyl-2-oxa-5a-androstan-3-one
|
| Systematic name |
N/A |
| Index name |
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-,
(5alpha,17beta)- |
| CAS number |
53-39-4 |
| Merck Index Number |
Merck 11, 6875 |
| Molecular formula |
C19-H30-O3 |
| Molecular weight |
306.443 g/mol |
| Legal status |
Prescription
only (US); DEA Schedule III (US) |
| Routes of administration |
Oral |
Visit Our Forums to Learn More About Anabolic Steroids
Last Revised: October
5, 2009
|